title: Histamine turnover in the brain of morphine-dependent mice.
abstract: The turnover of brain histamine was examined in mice implanted subcutaneously with a morphine pellet (50 mg free base). The numbers of naloxone-precipitated jumpings and body shakes were maximum 2 and 3 days after implantation, respectively. The brain tele-methylhistamine level significantly increased (50% to 115%) during 12 h-3 days after implantation of a morphine pellet, whereas the histamine level remained unchanged. The accumulation of tele-methylhistamine by pargyline treatment was significantly enhanced when pargyline was administered 12 h after implantation, suggesting an enhancement of histamine turnover. However, a similar degree of the tele-methylhistamine accumulation was induced by pargyline during 1-5 days after implantation, as compared with the accumulation in the control mice implanted with a placebo pellet. In mice undergoing morphine withdrawal by either the removal of morphine pellet or the treatment with naloxone 3 days after implantation, the degree of the pargyline-induced tele-methylhistamine accumulation or the (S)-alpha-fluoromethylhistidine (alpha-FMH)-induced histamine decrease was similar to that observed in the placebo pellet-control mice. The numbers of naloxone-precipitated jumpings and body shakes occurring in mice 3 days after implantation were not significantly affected by any of L-histidine, alpha-FMH or metoprine. These results suggest that turnover of histamine in the brain is enhanced by acute morphine treatment and returns to the normal rate in the stage of chronic treatment and remains unchanged during the state of withdrawal.
authors: Department of Pharmacology, Okayama University Medical School, Japan.
authors: R
authors: R
authors: Oishi
authors: M
authors: M
authors: Nishibori
authors: Y
authors: Y
authors: Itoh
authors: K
authors: K
authors: Saeki
authors: T
authors: T
authors: Fukuda
authors: Y
authors: Y
authors: Araki
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism*; D005493:Folic Acid Antagonists / Q000494:pharmacology; D006632:Histamine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D006639:Histidine / Q000494:pharmacology; D008297:Male; D008761:Methylhistamines / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D009021:Morphine Dependence / Q000378:metabolism*; D009270:Naloxone / Q000494:pharmacology; D010293:Pargyline / Q000494:pharmacology; D011739:Pyrimethamine / Q000031:analogs & derivatives / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome / Q000378:metabolism
chemical_list: D005493:Folic Acid Antagonists; D008761:Methylhistamines; C006308:metoprine; D009270:Naloxone; D006639:Histidine; C054284:alpha-fluoromethylhistamine; D006632:Histamine; D010293:Pargyline; C020404:tele-methylhistamine; D011739:Pyrimethamine